• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adj

Sally Furniss

Well-known member
Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine

http://www.sciencedirect.com/scienc...serid=10&md5=377700622323483dae0da94509cfd033

Joost Philippa Corresponding Author Contact Information, E-mail The Corresponding Author, Chantal Baas, Walter Beyer, Theo Bestebroer, Ron Fouchier, Derek Smith, c, Willem Schaftenaar and Ab Osterhaus
Institute of Virology, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
Rotterdam Zoo, P.O. Box 532, 3000 AM, Rotterdam, The Netherlands
Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK
Received 28 November 2006; revised 23 January 2007; accepted 30 January 2007. Available online 26 February 2007.

Abstract

Highly pathogenic avian influenza (HPAI) H5N1 virus infections have recently caused unprecedented morbidity and mortality in a wide range of avian species. European Commission directive 2005/744/EC allowed vaccination in zoos under strict conditions, while reducing confinement measures. Vaccination with a commercial H5N2 vaccine with vaccine doses adapted to mean body weight per species was safe, and proved immunogenic throughout the range of species tested, with some variations between and within taxonomic orders. After booster vaccination the overall homologous geometric mean titre (GMT) to the vaccine strain, measured in 334 birds, was 190 (95% CI: 152?236), and 80.5% of vaccinated birds developed a titre of ≥40. Titres to the HPAI H5N1 virus followed a similar trend, but were lower (GMT: 61 (95% CI: 49?76); 61% ≥ 40). The breadth of the immune response was further demonstrated by measuring antibody titres against prototype strains of four antigenic clades of currently circulating H5N1 viruses. These data indicate that vaccination should be regarded as a beneficial component of the preventive measures (including increased bio-security and monitoring) that can be undertaken in zoos to prevent an outbreak of and decrease environmental contamination by HPAI H5N1 virus, while alleviating confinement measures.

Keywords: Avian influenza; H5N1; Vaccination; Zoo; Clade
 
Back
Top